Jason W.D. Hearn

2.3k total citations · 1 hit paper
46 papers, 1.1k citations indexed

About

Jason W.D. Hearn is a scholar working on Pulmonary and Respiratory Medicine, Radiation and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Jason W.D. Hearn has authored 46 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Pulmonary and Respiratory Medicine, 17 papers in Radiation and 13 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Jason W.D. Hearn's work include Prostate Cancer Treatment and Research (27 papers), Prostate Cancer Diagnosis and Treatment (22 papers) and Advanced Radiotherapy Techniques (17 papers). Jason W.D. Hearn is often cited by papers focused on Prostate Cancer Treatment and Research (27 papers), Prostate Cancer Diagnosis and Treatment (22 papers) and Advanced Radiotherapy Techniques (17 papers). Jason W.D. Hearn collaborates with scholars based in United States, Germany and China. Jason W.D. Hearn's co-authors include M.M. Matuszak, Matthew J. Schipper, Robert T. Dess, Shruti Jolly, Payal Soni, James A. Hayman, Yilun Sun, Feng‐Ming Kong, Daniel E. Spratt and Theodore S. Lawrence and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and The Lancet Oncology.

In The Last Decade

Jason W.D. Hearn

41 papers receiving 1.1k citations

Hit Papers

1 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cardiac Events After Radiation Therapy: Combined Analysis of Prospective Multicenter Trials for Locally Advanced Non–Small-Cell Lung Cancer

2017 259 citations Robert T. Dess, Yilun Sun et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jason W.D. Hearn United States	18	760	287	240	137	134	46	1.1k
Nadine Abi‐Jaoudeh United States	18	389 0.5×	384 1.3×	126 0.5×	41 0.3×	115 0.9×	80	1.1k
Takuyo Kozuka Japan	17	1.1k 1.5×	484 1.7×	595 2.5×	75 0.5×	272 2.0×	67	1.6k
J. Wong United States	18	708 0.9×	253 0.9×	240 1.0×	39 0.3×	244 1.8×	63	1.3k
Tillmann Loch Germany	20	816 1.1×	167 0.6×	304 1.3×	35 0.3×	74 0.6×	69	1.2k
Bryan Donnelly Canada	27	1.9k 2.5×	342 1.2×	101 0.4×	271 2.0×	336 2.5×	85	3.0k
Robert H. Press United States	21	970 1.3×	200 0.7×	301 1.3×	25 0.2×	374 2.8×	100	1.4k
Matthew C. Abramowitz United States	19	915 1.2×	411 1.4×	301 1.3×	19 0.1×	143 1.1×	88	1.2k
J.J. Broerse Netherlands	25	822 1.1×	1.2k 4.1×	618 2.6×	36 0.3×	245 1.8×	118	1.9k
B. Pratt United Kingdom	16	211 0.3×	435 1.5×	72 0.3×	378 2.8×	151 1.1×	25	963
A. Bridier France	19	544 0.7×	493 1.7×	689 2.9×	11 0.1×	92 0.7×	75	1.1k

Countries citing papers authored by Jason W.D. Hearn

Since Specialization

Citations

This map shows the geographic impact of Jason W.D. Hearn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jason W.D. Hearn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jason W.D. Hearn more than expected).

Fields of papers citing papers by Jason W.D. Hearn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jason W.D. Hearn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jason W.D. Hearn. The network helps show where Jason W.D. Hearn may publish in the future.

Co-authorship network of co-authors of Jason W.D. Hearn

This figure shows the co-authorship network connecting the top 25 collaborators of Jason W.D. Hearn. A scholar is included among the top collaborators of Jason W.D. Hearn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jason W.D. Hearn. Jason W.D. Hearn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jackson, Will, Robert T. Dess, Angela Y. Jia, et al.. (2025). Androgen suppression with abiraterone acetate, leuprolide, PARP inhibition, and stereotactic body radiotherapy (ASCLEPIuS) in high-risk and node positive prostate cancer (PCa): Phase I multicenter results.. Journal of Clinical Oncology. 43(5_suppl). 387–387.

Sharifi, Nima, Arun Azad, Jason W.D. Hearn, et al.. (2024). HSD3B1 genotype and outcomes in metastatic hormone-sensitive prostate cancer with androgen deprivation therapy and enzalutamide: ARCHES. Cell Reports Medicine. 5(8). 101644–101644. 4 indexed citations

Lichter, Katie, Junzo Chino, Anna Rodrigues, et al.. (2024). Quantification of the environmental impact of radiotherapy and associated secondary human health effects: a multi-institutional retrospective analysis and simulation. The Lancet Oncology. 25(6). 790–801. 21 indexed citations

Edwards, Donna M., Caitlin A. Schonewolf, John D. Rice, et al.. (2024). Phase 2 Trial Assessing Toxicity of Personalized Response-Based Radiation Treatment in Patients With Locally Advanced Non-Small Cell Lung Cancer. International Journal of Radiation Oncology*Biology*Physics. 120(5). 1332–1343.

Campbell, Shauna R., Martin C. Tom, Shree Agrawal, et al.. (2021). Integrating Prostate-specific Antigen Kinetics into Contemporary Predictive Nomograms of Salvage Radiotherapy After Radical Prostatectomy. European Urology Oncology. 5(3). 304–313. 15 indexed citations

Armstrong, Wesley R., Kathleen Nguyen, Jérémie Calais, et al.. (2021). A Comprehensive Assessment of ⁶⁸Ga-PSMA-11 PET in Biochemically Recurrent Prostate Cancer: Results from a Prospective Multicenter Study on 2,005 Patients. Journal of Nuclear Medicine. 63(4). 567–572. 23 indexed citations

Sampayan, S., et al.. (2021). Megavolt bremsstrahlung measurements from linear induction accelerators demonstrate possible use as a FLASH radiotherapy source to reduce acute toxicity. Scientific Reports. 11(1). 17104–17104. 9 indexed citations

Schneider, Bryan J., Nofisat Ismaila, Joachim G.J.V. Aerts, et al.. (2019). Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline. Journal of Clinical Oncology. 38(7). 753–766. 105 indexed citations

Paradis, Kelly C., Charles S. Mayo, Dawn Owen, et al.. (2019). The Special Medical Physics Consult Process for Reirradiation Patients. Advances in Radiation Oncology. 4(4). 559–565. 41 indexed citations

10.

Christensen, Robert E., et al.. (2018). Adverse events in radiation oncology: A case series from wake up safe, the pediatric anesthesia quality improvement initiative. Pediatric Anesthesia. 29(3). 265–270. 19 indexed citations

11.

Piert, Morand, Prasad R. Shankar, Jeffrey S. Montgomery, et al.. (2018). Accuracy of tumor segmentation from multi-parametric prostate MRI and 18F-choline PET/CT for focal prostate cancer therapy applications. EJNMMI Research. 8(1). 23–23. 22 indexed citations

12.

Jackson, Will, Krithika Suresh, Vasu Tumati, et al.. (2018). Intermediate Endpoints After Postprostatectomy Radiotherapy: 5-Year Distant Metastasis to Predict Overall Survival. European Urology. 74(4). 413–419. 24 indexed citations

13.

Jolly, Shruti, Yilun Sun, Peter G. Hawkins, et al.. (2017). Individualizing Radiation Dose in Locally Advanced Non–Small Cell Lung Cancer Patients Using Pretreatment Serum MicroRNA Signatures. International Journal of Radiation Oncology*Biology*Physics. 98(1). 222–222. 2 indexed citations

14.

Ramey, Stephen J., Shree Agrawal, Matthew C. Abramowitz, et al.. (2017). Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer. European Urology. 74(1). 99–106. 29 indexed citations

15.

Sun, Yilun, Peter G. Hawkins, Nan Bi, et al.. (2017). Serum MicroRNA Signature Predicts Response to High-Dose Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer. International Journal of Radiation Oncology*Biology*Physics. 100(1). 107–114. 29 indexed citations

16.

Hearn, Jason W.D., Gregory M.M. Videtic, T. Djemil, & Kevin L. Stephans. (2014). Salvage Stereotactic Body Radiation Therapy (SBRT) for Local Failure After Primary Lung SBRT. International Journal of Radiation Oncology*Biology*Physics. 90(2). 402–406. 51 indexed citations

17.

Tretyakova, Irina, Jason W.D. Hearn, Eryu Wang, Scott C. Weaver, & Peter Pushko. (2014). DNA Vaccine Initiates Replication of Live Attenuated Chikungunya Virus In Vitro and Elicits Protective Immune Response in Mice. The Journal of Infectious Diseases. 209(12). 1882–1890. 61 indexed citations

18.

Hearn, Jason W.D., et al.. (2014). Integrative Radiogenomic Profiling Identifies BRAF Mutations as Novel Radiotherapeutic Targets in Adenocarcinomas of the Lung. International Journal of Radiation Oncology*Biology*Physics. 90(1). S101–S102.

19.

Hays, John L., Anne M. Noonan, Christina M. Annunziata, et al.. (2013). Phase I/Ib study of the PARP inhibitor (PARPi) olaparib (O/AZD2281) in combination with carboplatin (C) in ovarian cancer (OvCa) patients with BRCA1/2 mutations (OvCaMUT+) and high grade serous OvCa (HGSOC) with low genetic risk (NCT00647062). Gynecologic Oncology. 130(1). e11–e11. 1 indexed citations

20.

Tobalske, Bret W., Jason W.D. Hearn, & Douglas R. Warrick. (2009). Aerodynamics of intermittent bounds in flying birds. Experiments in Fluids. 46(5). 963–973. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact